ArticleAbdominal radiology (New York)2026
Quantitative imaging biomarkers as prognostic indicators in squamous cell cervical carcinoma: a retrospective cohort analysis.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate quantitative imaging biomarkers, including MRI tumor size, apparent diffusion coefficient (ADC), arterial-phase enhancement, and PET maximum standardized uptake value (SUVmax), as prognostic indicators of overall survival (OS), recurrence-free survival (RFS), and treatment response in cervical squamous cell carcinoma (SCC). MATERIALS AND
methodsFifty patients with biopsy-proven SCC who underwent pre- and post-treatment MRI and FDG-PET/CT were retrospectively analyzed. Tumor dimensions (axial, sagittal), ADC, SUVmax, and arterial enhancement were assessed. Survival was estimated by Kaplan-Meier, and associations with OS and RFS were tested using Cox regression. Logistic regression was used to determine predictors of treatment response according to RECIST and PERCIST criteria.
resultsTumor size, SUVmax, and ADC changed significantly post-treatment (p < 0.001). Persisting arterial enhancement was seen in 35% of tumors. Higher post-treatment SUVmax predicted worse OS (HR = 1.078, p = 0.008) and RFS (HR = 1.049, p = 0.046). Larger residual sagittal tumor size showed borderline associations with inferior OS (HR = 1.38, p = 0.089) and RFS (HR = 1.31, p = 0.057). Increases in tumor size significantly correlated with persistent arterial enhancement (axial OR = 1.58, p = 0.025; sagittal OR = 1.93, p = 0.002). Persistent enhancement trended toward worse RFS (HR ≈ 2.24, p = 0.107). In multivariable analysis, post-treatment pelvic lymph node positivity remained independently associated with poorer RFS. Baseline ADC predicted metabolic response: a higher pre-treatment ADC was associated with a failure to achieve a partial metabolic response per PERCIST (OR = 1.007, p = 0.015).
conclusionPost-treatment SUVmax, residual tumor size, arterial enhancement, and pelvic lymph node involvement are key prognostic indicators in cervical SCC. Persistent enhancement may reflect treatment-resistant vascularity. Integrating these biomarkers into clinical workflows may improve risk stratification and guide personalized management.
Indexed as
Identifiers
41454940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.